Posted by shellson2 on 5th of Oct 2025 at 03:19 pm
ARVN--Look for this to move potentially.
NEW HAVEN, Conn., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Arvinas,
Inc. (NASDAQ:
ARVN), a
clinical-stage biotechnology company creating a new class of drugs
based on targeted protein degradation, today announced positive
pharmacokinetic, pharmacodynamic, and biomarker data from two Phase
1 clinical trials evaluating ARV-102, an oral, brain-penetrant
investigational PROTAC degrader of leucine-rich repeat kinase 2
(LRRK2). Results were presented at the International Congress of
Parkinson's Disease and Movement Disorders® (MDS 2025) in
Honolulu.
"We are particularly excited by the CSF proteomics results,
which demonstrate modulation of lysosomal and microglial pathways
that are known to be associated with neurodegenerative diseases,"
said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer of Arvinas.
"We believe these findings support the intensified development of
ARV-102 in ongoing studies of patients with Parkinson's disease,
and in future studies of patients with progressive supranuclear
palsy."
The company presented data from two trials: ARV-102-101, a
first-in-human trial of ARV-102 in healthy volunteers, and
ARV-102-103, a trial in patients with Parkinson's disease
ARVN--Look for this to move
Posted by shellson2 on 5th of Oct 2025 at 03:19 pm
ARVN--Look for this to move potentially.
NEW HAVEN, Conn., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced positive pharmacokinetic, pharmacodynamic, and biomarker data from two Phase 1 clinical trials evaluating ARV-102, an oral, brain-penetrant investigational PROTAC degrader of leucine-rich repeat kinase 2 (LRRK2). Results were presented at the International Congress of Parkinson's Disease and Movement Disorders® (MDS 2025) in Honolulu.
"We are particularly excited by the CSF proteomics results, which demonstrate modulation of lysosomal and microglial pathways that are known to be associated with neurodegenerative diseases," said Noah Berkowitz, M.D., Ph.D., Chief Medical Officer of Arvinas. "We believe these findings support the intensified development of ARV-102 in ongoing studies of patients with Parkinson's disease, and in future studies of patients with progressive supranuclear palsy."
The company presented data from two trials: ARV-102-101, a first-in-human trial of ARV-102 in healthy volunteers, and ARV-102-103, a trial in patients with Parkinson's disease
ARVN--cleared 4/30/25 high today, heavier
Posted by shellson2 on 16th of Oct 2025 at 01:26 pm
ARVN--cleared 4/30/25 high today, heavier than usual Vol.
ARVN—up big this am
Posted by shellson2 on 18th of Nov 2025 at 08:29 am
ARVN—up big this am
Nice
Posted by morton7 on 18th of Nov 2025 at 11:22 am
Nice
At 8 month High now.
Posted by shellson2 on 7th of Nov 2025 at 03:43 pm
At 8 month High now. Had a massive drop in March ($18 to $8).
Chart looking better and better.
Posted by shellson2 on 30th of Oct 2025 at 10:45 am
Chart looking better and better.